Multiple Endocrine Neoplasia Type 2 — designated MEN2, a rare but clinically critical autosomal dominant hereditary cancer syndrome caused by germline gain-of-function pathogenic variants in the RET proto-oncogene (chromosome 10q11.21, encoding a receptor tyrosine kinase with cadherin-like and cysteine-rich extracellular domains and an intracellular kinase domain, normally activated by the GDNF ligand family through GFRα co-receptors and required for the development of the enteric nervous system, kidney, and neural crest-derived tissues; RET gain-of-function mutations produce constitutive ligand-independent kinase activation driving unregulated proliferation, survival, and transformation in neuroendocrine-lineage cells derived from neural crest progenitors — specifically C cells of the thyroid, chromaffin cells of the adrenal medulla, and parathyroid chief cells) — subdivided into two clinically distinct subtypes with different RET mutation spectra and penetrance profiles: MEN2A (accounting for approximately 95% of all MEN2 cases, caused predominantly by RET mutations at extracellular cysteine residues in exon 10 [codons 609, 611, 618, 620] and exon 11 [codon 634 — C634R, C634Y, C634W, the most common MEN2A mutations], characterized by medullary thyroid carcinoma [virtually 100% lifetime penetrance in codon 634 carriers], pheochromocytoma [50% lifetime risk], and primary hyperparathyroidism [20–30%]; and MEN2B [5% of MEN2 cases, caused predominantly by the RET M918T mutation in exon 16, the most common single-nucleotide MEN2B mutation, with rare alternative RET A883F mutations, characterized by medullary thyroid carcinoma [essentially 100% penetrance and most aggressive MEN2 subtype — MTC often presenting in infancy in M918T carriers, with lymph node metastases in the first years of life], pheochromocytoma [40–50%], mucosal neuromas [pathognomonic — ganglioneuromatosis of lips, tongue, and gastrointestinal tract], and Marfanoid habitus with musculoskeletal features resembling Marfan syndrome — without lens subluxation or aortic dilation], with the genotype-phenotype correlation in MEN2 so strong that ATA risk categories (Highest/D: codon 918; High/C: codon 634, 883; Moderate/B: codons 609, 611, 618, 620, 630, 768, 790, 791, 804, 891) directly determine the timing and extent of prophylactic thyroidectomy recommendation in RET carriers) — arising from constitutive RET kinase activation that drives parafollicular C cell proliferation from C cell hyperplasia through C cell carcinoma (medullary thyroid carcinoma, MTC) in a histopathological sequence whose timing is compressed dramatically in highest-risk codon 918 and codon 634 carriers versus moderate-risk carriers, and whose molecular biomarker — serum calcitonin — is the most sensitive and specific serological tumor marker in all of hereditary cancer medicine, with calcitonin doubling time serving as the most powerful independent prognostic variable in MEN2-associated MTC; the overall population prevalence of MEN2 is approximately 1 in 35,000, with MEN2B de novo mutations accounting for approximately 75% of cases (no family history identifiable) and requiring a high index of clinical suspicion in any infant or child with mucosal neuromas, Marfanoid features, or constipation — making MEN2 the hereditary syndrome where de novo germline diagnosis in a young child with Marfanoid habitus triggers the prophylactic thyroidectomy within weeks of genetic confirmation that prevents the otherwise-inevitable pediatric MTC.
MEN2 technology platforms — encompassing the clinical genetics platforms where RET germline sequencing identifies the causative gain-of-function variant and assigns the ATA risk category that determines the recommended prophylactic thyroidectomy age — within 6 months in ATA-D M918T carriers, by age 5 in ATA-C codon 634/883 carriers, by age 5–10 in ATA-B moderate-risk carriers — and where cascade genetic testing of at-risk first-degree relatives identifies codon-specific RET variants in children who can undergo prophylactic thyroidectomy before MTC development; the endocrine biochemistry laboratory platforms performing the serial calcitonin and CEA measurements that are the definitive MEN2-MTC surveillance and post-operative disease monitoring tools — basal calcitonin for biochemical screening (calcitonin >100 pg/mL highly predictive of MTC; >500 pg/mL predicting lymph node metastases), pentagastrin-stimulated calcitonin for pre-operative staging in centers where pentagastrin is available, and calcitonin doubling time (CDT) measurement for post-operative recurrence prediction and systemic therapy timing; the urine catecholamine and plasma metanephrine laboratory platforms performing the annual pheochromocytoma biochemical screening mandatory in all MEN2 carriers — 24-hour urinary catecholamines/metanephrines or plasma fractionated metanephrines — before any planned thyroid or parathyroid surgery given the risk of hypertensive crisis from unsuspected pheochromocytoma during surgical anaesthesia; the radiological surveillance platforms — neck ultrasound for post-operative MTC bed surveillance and lymph node assessment, CT neck/chest/abdomen/pelvis or MRI for locoregional and distant MTC staging, MIBG scintigraphy and 18F-DOPA PET or 68Ga-DOTATATE PET for functional pheochromocytoma localization and MTC staging, MRI or CT for pheochromocytoma adrenal characterization; the endocrine surgery platforms where prophylactic thyroidectomy (total thyroidectomy with central neck dissection) — the single most important preventive intervention in MEN2 and one of the most impactful preventive surgical procedures in hereditary cancer medicine when performed before MTC development — is scheduled and documented, and where laparoscopic adrenalectomy for pheochromocytoma is performed after mandatory alpha-adrenergic blockade (phenoxybenzamine or doxazosin) with beta-blockade addition; and the oncological treatment platforms delivering vandetanib (RET/EGFR/VEGFR multi-kinase inhibitor, 300 mg daily, FDA-approved first-line for unresectable locally advanced or metastatic MTC) and cabozantinib (RET/MET/VEGFR2 inhibitor, 60 mg daily, FDA-approved second-line for progressive MTC) and the selective RET-inhibitors pralsetinib (BLU-667, FDA-approved for RET-mutant MTC) and selpercatinib (LOXO-292, FDA-approved for RET-mutant MTC) — a class of drugs that specifically targets the constitutively active RET kinase driving MEN2 MTC with response rates of 60–80% in RET M918T-mutant MTC — must maintain the availability and performance standards required by the prophylactic-surgery-timing-critical, catecholamine-screening-mandatory, calcitonin-doubling-time-dependent, and selective-RET-inhibitor-treatment-complex demands of this hereditary neuroendocrine syndrome. This guide explains why MEN2 tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the thyroid, adrenal, parathyroid, and oncological obligations that define modern MEN2 care.
Why Multiple Endocrine Neoplasia Type 2 Tech Platforms Require Specialized Monitoring Attention
MEN2 management is defined by several clinically critical biochemical, surgical, and oncological obligations: the prophylactic thyroidectomy timing imperative — RET ATA risk category determines the window between MEN2 carrier identification and prophylactic thyroidectomy that prevents MTC; in ATA-D M918T carriers the recommended prophylactic thyroidectomy within the first 6 months of life requires immediate RET genotyping platform availability from the moment a de novo MEN2B infant is identified; the mandatory pheochromocytoma biochemical exclusion before any MEN2 surgical procedure — urine catecholamine and plasma metanephrine platform unavailability before planned thyroid or adrenal surgery creates unsuspected pheochromocytoma surgical risk and potentially fatal intraoperative hypertensive crisis; the calcitonin doubling time calculation dependency — sequential serum calcitonin measurements whose precision and laboratory platform reliability directly determine CDT, the prognostic metric that guides systemic RET inhibitor initiation timing; and the selective RET inhibitor treatment continuity — pralsetinib and selpercatinib for RET-mutant MTC require oncology platform availability for daily oral dosing documentation, toxicity monitoring, and response assessment throughout treatment courses.
RET germline sequencing platforms with rapid ATA risk category assignment are the highest-priority diagnostic action for newly identified MEN2 patients and at-risk pediatric relatives. RET codon-specific genotyping from newborn or early childhood samples in MEN2 families requires immediate molecular genetics laboratory platform availability and result communication to the endocrine surgery team scheduling prophylactic thyroidectomy. Monitor RET germline genotyping platforms at 1-minute intervals during laboratory hours.
Pheochromocytoma biochemical screening platforms are mandatory before every MEN2 surgical procedure. 24-hour urine catecholamine/metanephrine and plasma fractionated metanephrine measurement must be available and results reviewed before general anaesthesia for thyroid, parathyroid, or adrenal procedures in MEN2 carriers. Monitor catecholamine biochemistry platforms at 1-minute intervals during laboratory hours.
Calcitonin measurement platforms determine MTC staging, post-operative biochemical cure assessment, and recurrence monitoring. Basal serum calcitonin and CEA serial measurement with CDT calculation require uninterrupted laboratory platform availability for post-thyroidectomy surveillance and metastatic MTC management. Monitor calcitonin measurement platforms at 1-minute intervals during laboratory hours.
Oncology platforms for selective RET inhibitor therapy require continuous availability during pralsetinib and selpercatinib treatment. Daily oral selective RET inhibitor therapy for unresectable or metastatic RET-mutant MTC requires oncology platform availability for toxicity documentation, dose modification, response assessment, and drug dispensing coordination. Monitor oncology treatment platforms at 1-minute intervals during oncology clinical hours.
What to Monitor on a Multiple Endocrine Neoplasia Type 2 Care Tech Platform
RET Germline Genetics, Cascade Testing, and ATA Risk Stratification
Monitor RET germline sequencing records (targeted hotspot sequencing of RET exons 10, 11, 13, 14, 15, 16 for codon-specific MEN2A/MEN2B variant identification — exon 10 codons 609, 611, 618, 620; exon 11 codon 634; exon 13 codon 768; exon 14 codon 804, 790, 791; exon 15 codon 891; exon 16 codon 918; comprehensive RET panel sequencing for atypical MEN2 presentations or newly identified germline variants of uncertain significance; variant classification per ACMG/AMP criteria; de novo RET mutation confirmation by parental testing; somatic RET mutation testing in MTC tumor tissue for RET inhibitor eligibility), ATA risk category assignment records (ATA-D/Highest: codon 918; ATA-C/High: codons 634, 883; ATA-B/Moderate: all other pathogenic RET codons; risk category documentation triggering prophylactic thyroidectomy timing protocol; calcitonin threshold-guided thyroidectomy for moderate-risk carriers who have not undergone prophylactic surgery), and cascade family testing records (at-risk first-degree relatives — children tested at birth or early infancy in ATA-D/C families; children tested by age 3–5 for ATA-B families; predictive RET testing protocol; pediatric testing governance documentation; disclosure and genetic counseling records) — at a 1-minute interval during laboratory hours.
Medullary Thyroid Carcinoma — Biochemistry, Surgery, and Surveillance
Monitor MTC calcitonin records (basal serum calcitonin — annual in RET carriers without prior thyroidectomy; serial post-operative calcitonin measurements at 3 months, 6 months, and annually — undetectable calcitonin confirming biochemical cure; detectable post-operative calcitonin requiring surveillance and CDT calculation; calcitonin doubling time — CDT <6 months: high risk requiring cross-sectional imaging and consideration of systemic therapy; CDT 6–24 months: intermediate risk requiring imaging; CDT >24 months: low risk allowing continued surveillance; pentagastrin-stimulated calcitonin where available for early MTC detection in calcitonin-borderline carriers), MTC CEA records (basal serum CEA — annual post-operative measurement; CEA doubling time parallel to CDT for prognostic stratification; discordant calcitonin/CEA doubling time signaling dedifferentiation), thyroid surgery records (prophylactic thyroidectomy — total thyroidectomy with central compartment lymph node dissection; age at prophylactic surgery documentation; histopathological findings — C cell hyperplasia only versus microscopic MTC versus macroscopic MTC; specimen calcitonin staining; surgeon specimen intraoperative calcitonin measurement for real-time residual disease assessment; therapeutic total thyroidectomy for established MTC — extent of nodal dissection — central, ipsilateral lateral, bilateral lateral — based on calcitonin level and imaging stage; intraoperative findings documentation; margin status; number of involved nodes and extranodal extension), and post-operative thyroid records (levothyroxine replacement — TSH suppression not required for MTC unlike differentiated thyroid cancer; post-operative hypocalcaemia management; parathyroid autotransplantation documentation; vocal cord function post-operative assessment) — at a 1-minute interval during laboratory and clinical hours. Alert immediately — delayed calcitonin processing after prophylactic thyroidectomy denies the surgical team the biochemical cure confirmation that MTC-free surgery produces.
Pheochromocytoma — Biochemistry, Localization, and Surgical Management
Monitor pheochromocytoma biochemistry records (annual plasma fractionated metanephrines — most sensitive pheochromocytoma screening test in MEN2 carriers, from age 11 in ATA-D carriers and age 16 in ATA-B/C carriers; 24-hour urinary catecholamines and fractionated metanephrines; biochemical confirmation of pheochromocytoma — elevated normetanephrine/metanephrine with anatomical imaging; alpha-adrenergic blockade pre-operative preparation records — phenoxybenzamine titration for 10–14 days pre-operatively; blood pressure and heart rate response to alpha blockade; beta-blocker addition after adequate alpha blockade; bowel preparation records), pheochromocytoma imaging records (CT adrenal with contrast — bilateral adrenal mass characterization; MRI adrenal T2 bright signal pheochromocytoma morphology; 123I-MIBG scintigraphy for functional localization and bilateral disease assessment; 18F-DOPA PET — superior sensitivity to MIBG for MEN2 pheochromocytoma; 68Ga-DOTATATE PET for SSTR-expressing pheochromocytoma localization; 18F-FDG PET for malignant or high-grade pheochromocytoma), pheochromocytoma surgery records (laparoscopic adrenalectomy — cortical-sparing adrenalectomy preferred for bilateral MEN2 pheochromocytoma to preserve adrenal cortical function and avoid lifelong steroid dependence; total adrenalectomy for large or bilateral tumors without cortical sparing; intraoperative haemodynamic management documentation — BP and heart rate monitoring, vasoactive drug records; post-operative cortisol and aldosterone assessment for cortical function), and malignant pheochromocytoma records (malignant pheochromocytoma defined by metastatic disease — locally invasive but not in itself diagnostic; 131I-MIBG therapy for MIBG-avid malignant pheochromocytoma; 177Lu-DOTATATE for SSTR-positive malignant disease; sunitinib/cyclophosphamide-vincristine-dacarbazine chemotherapy records) — at a 1-minute interval during laboratory and clinical hours.
Primary Hyperparathyroidism (MEN2A)
Monitor parathyroid biochemistry records (serum calcium — annual from age 11 in MEN2A carriers; intact PTH — annual; 24-hour urinary calcium for nephrolithiasis risk; DXA bone mineral density — in confirmed hyperparathyroidism), parathyroid imaging records (neck ultrasound concurrent with thyroid ultrasound for parathyroid gland characterization; sestamibi scintigraphy for adenoma localization; 4D CT if re-operation required), and parathyroid surgery records (focused parathyroidectomy for single adenoma — concurrent with thyroidectomy where possible; subtotal parathyroidectomy for multigland disease; intraoperative PTH — confirmation of adequate resection; parathyroid autotransplantation when total parathyroidectomy required) — at a 1-minute interval during laboratory and clinical hours.
MEN2B-Specific Surveillance — Mucosal Neuromas and Marfanoid Features
Monitor MEN2B clinical records (mucosal neuroma assessment — lips, tongue, buccal mucosa, conjunctiva; ganglioneuromatosis GI tract — chronic constipation from colonic ganglioneuromatosis; barium enema or colonoscopy for megacolon; Marfanoid skeletal survey — pes cavus, pectus excavatum, scoliosis; ophthalmological records — corneal nerve fiber visualization; orthopedic assessment records for MEN2B musculoskeletal features), and pediatric developmental records (early growth and developmental surveillance in MEN2B children; nutritional assessment for ganglioneuromatosis-related malabsorption; pediatric neurology records for peripheral neuropathy) — at a 1-minute interval during clinical hours.
MTC Neck and Distant Disease Surveillance
Monitor neck ultrasound records (annual neck ultrasound for thyroid bed, central compartment, and lateral neck lymph node surveillance in post-thyroidectomy MEN2-MTC patients; fine needle aspiration cytology for suspicious lymph nodes; calcitonin washout in FNA cytology), cross-sectional staging records (CT neck/chest/abdomen/pelvis for distant MTC staging — elevated calcitonin >150 pg/mL or rising CDT; liver lesion characterization; bone metastasis assessment), functional imaging records (68Ga-DOTATATE PET for SSTR-positive MTC localization; 18F-DOPA PET for catecholamine-pathway MTC; 18F-FDG PET for high-grade or rapidly progressive MTC), and MTC locoregional treatment records (external beam radiation therapy for unresectable locoregional MTC — dosimetry and treatment records; intraoperative calcitonin-guided lymph node dissection) — at a 1-minute interval during clinical and radiology hours.
Systemic Oncological Treatment — Selective RET Inhibitors and Multi-Kinase Inhibitors
Monitor selective RET inhibitor records (selpercatinib — LOXO-292, 160 mg twice daily oral; response assessment by RECIST; QTc monitoring; hepatotoxicity LFT monitoring; hypertension management; interstitial lung disease surveillance; dry eye/wound healing records; selpercatinib dose interruption and modification records), pralsetinib records (BLU-667, 400 mg once daily oral; haematological toxicity monitoring — anaemia, neutropenia; constipation/diarrhoea management; hepatotoxicity records; pneumonitis surveillance; dose modification records), vandetanib records (300 mg daily — QTc prolongation monitoring via ECG; diarrhoea/rash/hypertension management; hypothyroidism biochemistry; vandetanib dose modification), cabozantinib records (60 mg daily — hepatic function monitoring; hypertension; wound healing; fistula/perforations; dose modifications), and clinical trial records (novel RET inhibitor combination trials; PRRT for SSTR-positive MTC; systemic chemotherapy records for dedifferentiated MTC) — at a 1-minute interval during oncology clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. MEN2 management coordinates across clinical genetics (RET sequencing, ATA risk stratification, and cascade family testing — particularly urgent in de novo MEN2B pediatric cases), endocrinology (calcitonin/CEA surveillance and pheochromocytoma biochemical screening), endocrine surgery (prophylactic thyroidectomy scheduling and pheochromocytoma adrenalectomy), nuclear medicine (MIBG, DOPA-PET, and 68Ga-DOTATATE imaging), medical oncology (selective RET inhibitor and multi-kinase inhibitor therapy), radiation oncology (locoregional MTC radiotherapy), genetic counseling (cascade pediatric testing and reproductive counseling), and hereditary endocrine tumor clinic coordination — authentication failures block access across all these disciplines and, in de novo MEN2B pediatric cases, delay the RET genotype result communication that triggers the urgent prophylactic thyroidectomy preventing infant MTC metastasis.
SSL Certificates
Monitor SSL certificate expiry across all molecular genetics laboratory systems, calcitonin and catecholamine biochemistry laboratory platforms, radiology scheduling portals, MIBG and PET imaging reporting systems, endocrine surgery scheduling and documentation platforms, oncology treatment platforms, and hereditary endocrine tumor clinic coordination portals. Certificate errors blocking calcitonin results from displaying in clinical systems delay the CDT calculation that guides systemic RET inhibitor initiation for metastatic MTC patients.
HIPAA and MEN2 Patient Privacy Considerations
MEN2 technology platforms handle highly sensitive PHI for patients and families carrying germline RET pathogenic variants — a genetic diagnosis with direct implications for pediatric family members requiring prophylactic thyroidectomy, and whose RET codon-specific variant determines lifetime MTC, pheochromocytoma, and hyperparathyroidism risks. Records include germline RET sequencing with ATA risk category assignment, longitudinal calcitonin and CEA surveillance documenting MTC disease trajectory, pheochromocytoma biochemistry and adrenal surgical records, selective RET inhibitor treatment records for metastatic MTC, and pediatric prophylactic thyroidectomy records for children identified as RET carriers through cascade family testing.
Germline RET data triggers GINA protections for employment and health insurance genetic discrimination. Pediatric RET testing records — generated when at-risk infants or children undergo prophylactic germline genotyping to determine prophylactic thyroidectomy timing — require particular HIPAA safeguarding given their pediatric subject age and the reproductive implications for parents whose child's de novo MEN2B RET M918T mutation was not inherited from either parent.
Alerting Strategy for MEN2 Tech Platforms
Immediate 24/7 alerting for authentication: MEN2 care coordination is continuous across genetic testing, biochemical surveillance, surgical planning, and oncological treatment — with de novo MEN2B pediatric cases requiring real-time coordination between genetics and endocrine surgery.
Immediate laboratory-hours alerting for RET germline genotyping platforms: ATA risk category-determining RET sequencing for newborn and pediatric MEN2 family members requires immediate molecular genetics laboratory platform availability, particularly in de novo MEN2B cases where prophylactic thyroidectomy timing is urgent.
Immediate laboratory-hours alerting for pheochromocytoma biochemistry platforms: Plasma metanephrines and 24-hour urinary catecholamines must be available before every MEN2 surgical procedure to exclude pheochromocytoma.
Immediate laboratory-hours alerting for calcitonin measurement platforms: Basal calcitonin and CDT calculation require continuous laboratory availability for post-thyroidectomy MTC surveillance and metastatic MTC management.
Immediate clinical-hours alerting for neck ultrasound and staging imaging platforms: Annual neck ultrasound and cross-sectional staging CT/MRI require reliable radiology scheduling and reporting platform availability.
Immediate oncology-hours alerting for selective RET inhibitor treatment platforms: Selpercatinib, pralsetinib, vandetanib, and cabozantinib documentation for unresectable or metastatic MTC requires reliable oncology platform availability.
Immediate clinical-hours alerting for prophylactic thyroidectomy scheduling platforms: Prophylactic thyroidectomy scheduling for RET carriers — particularly ATA-D pediatric carriers requiring surgery within 6 months of diagnosis — requires immediate surgical scheduling platform availability.
Sustained-failure alert (10–15 minutes): Parathyroid biochemistry platforms (MEN2A), MEN2B neurological and developmental surveillance platforms, and genetic counseling coordination platforms.
30-day advance warning: SSL certificates across all domains.
Status Page for MEN2 Care Team Communication
A real-time status page gives endocrinologists coordinating annual calcitonin/CEA surveillance and pheochromocytoma biochemical screening, endocrine surgeons scheduling prophylactic thyroidectomy for pediatric RET carriers and laparoscopic adrenalectomy for pheochromocytoma, nuclear medicine physicians performing MIBG and DOPA-PET localization, medical oncologists prescribing selpercatinib, pralsetinib, vandetanib, and cabozantinib for metastatic MTC, clinical geneticists assigning ATA risk categories and coordinating cascade pediatric testing, and genetic counselors providing reproductive counseling for MEN2 families immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in MEN2 surveillance calendar templates, hereditary endocrine tumor clinic appointment reminders, and prophylactic thyroidectomy scheduling systems.
Vigilmon Setup for MEN2 Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | RET germline sequencing and ATA risk stratification | 1 min | Slack + PagerDuty (lab hours) | | Plasma metanephrines (pheochromocytoma screening) | 1 min | Slack + PagerDuty (lab hours) | | 24-hour urinary catecholamines (pheochromocytoma) | 1 min | Slack + PagerDuty (lab hours) | | Serum calcitonin (MTC surveillance and CDT) | 1 min | Slack + PagerDuty (lab hours) | | Serum CEA (MTC biomarker) | 1 min | Slack + PagerDuty (lab hours) | | Serum calcium and PTH (MEN2A hyperparathyroidism) | 1 min | Slack + PagerDuty (lab hours) | | Neck ultrasound scheduling and reporting | 1 min | Slack + PagerDuty (clinical hours) | | CT/MRI staging (neck/chest/abdomen/pelvis) | 1 min | Slack + PagerDuty (clinical hours) | | MIBG scintigraphy (pheochromocytoma localization) | 1 min | Slack + PagerDuty (clinical hours) | | 18F-DOPA PET / 68Ga-DOTATATE PET | 1 min | Slack + PagerDuty (clinical hours) | | Prophylactic thyroidectomy scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Adrenalectomy scheduling and operative documentation | 1 min | Slack + PagerDuty (clinical hours) | | Selpercatinib / pralsetinib treatment documentation | 1 min | Slack + PagerDuty (oncology hours) | | Vandetanib / cabozantinib treatment documentation | 1 min | Slack + PagerDuty (oncology hours) | | QTc monitoring (vandetanib/selpercatinib) | 1 min | Slack + PagerDuty (oncology hours) | | Cascade pediatric RET testing (family members) | 1 min | Slack + PagerDuty (lab hours) | | MEN2B neurological and developmental surveillance | 2 min | Slack (clinical hours) | | Genetic counseling and reproductive planning | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure RET germline sequencing and ATA risk stratification platforms with immediate laboratory-hours alerting — critical for pediatric de novo MEN2B prophylactic thyroidectomy timing
- Add plasma metanephrine and 24-hour catecholamine platforms with immediate laboratory-hours alerting — mandatory pre-surgical pheochromocytoma exclusion
- Configure serum calcitonin and CEA measurement platforms with immediate laboratory-hours alerting — MTC disease monitoring and CDT calculation
- Add serum calcium and PTH platforms with immediate laboratory-hours alerting — MEN2A hyperparathyroidism surveillance
- Configure neck ultrasound scheduling and reporting platforms with immediate clinical-hours alerting
- Add CT/MRI staging platforms with immediate clinical-hours alerting
- Configure MIBG scintigraphy and DOPA/DOTATATE PET platforms with immediate clinical-hours alerting
- Add prophylactic thyroidectomy scheduling platforms with immediate clinical-hours alerting
- Configure adrenalectomy scheduling and operative documentation platforms with immediate clinical-hours alerting
- Add selpercatinib and pralsetinib treatment documentation platforms with immediate oncology-hours alerting
- Configure vandetanib and cabozantinib treatment platforms with immediate oncology-hours alerting
- Add QTc monitoring platforms with immediate oncology-hours alerting
- Configure cascade pediatric RET testing platforms with immediate laboratory-hours alerting
- Add MEN2B surveillance platforms with sustained-failure alerting
- Configure genetic counseling coordination platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to MEN2 surveillance calendar templates and hereditary endocrine tumor clinic coordination platforms
Conclusion
MEN2 technology platforms are embedded in clinical decisions where RET germline genotyping platform availability — the test that assigns the ATA risk category determining the prophylactic thyroidectomy timing window for a pediatric RET carrier — determines whether a 3-year-old child of an MEN2A proband known to carry the RET C634R codon 634 mutation undergoes site-specific RET codon 634 predictive testing that returns a positive result within the 48-hour laboratory processing window, triggering the surgical scheduling for prophylactic total thyroidectomy before age 5 that will prevent the medullary thyroid carcinoma that, in the absence of prophylactic surgery, would develop in virtually 100% of codon 634 carriers before their 30th birthday with bilateral C-cell hyperplasia progressing through microscopic MTC to macroscopic disease and eventual cervical lymph node metastasis — a trajectory that prophylactic thyroidectomy at age 3–4 interrupts completely, with post-operative calcitonin becoming undetectable and remaining so, giving the child a normal life expectancy without MTC; where plasma metanephrine platform availability before a scheduled prophylactic thyroidectomy in a 17-year-old MEN2B carrier with the M918T mutation — who has already undergone thyroidectomy at 6 months of age and is now attending for annual surveillance — determines whether the anesthesiology team receives the plasma metanephrine result showing borderline elevation of normetanephrine before the planned procedure, triggering the MRI adrenal that identifies a 2.1 cm right adrenal pheochromocytoma, prompting 10 days of phenoxybenzamine alpha blockade before laparoscopic adrenalectomy is performed safely rather than proceeding to thyroid bed resection under general anaesthesia with unsuspected pheochromocytoma whose intraoperative catecholamine crisis could be fatal; and where selpercatinib treatment documentation platform availability during maintenance therapy for a 38-year-old MEN2A carrier with progressive M918T-negative progressive metastatic MTC on selpercatinib 160 mg twice daily — where the oncologist is documenting month 8 response assessment showing durable partial response with 52% target lesion reduction and excellent tolerability, and scheduling next month's LFT monitoring and QTc ECG — cannot be disrupted by oncology system failures that delay selpercatinib prescription renewal or miss the LFT elevation signaling hepatotoxicity that requires dose interruption before progression to severe hepatic injury. A RET genotyping platform unavailable when the ATA risk category-determining codon is being sequenced for a newborn in an MEN2B family, a plasma metanephrine platform unavailable before a surgical procedure in a known MEN2 carrier, a selpercatinib treatment documentation system disrupted during monthly toxicity monitoring for a metastatic MTC patient experiencing durable response — these are not IT incidents. They are clinical disruptions in the management of the hereditary neuroendocrine syndrome where RET codon-specific genotyping determines prophylactic surgery timing with accuracy unprecedented in hereditary cancer prevention, where mandatory pre-operative pheochromocytoma biochemical exclusion prevents surgical catastrophe, where calcitonin doubling time guides the transition from surveillance to systemic RET inhibitor therapy, and where selective RET inhibitors achieve 60–80% response rates in M918T-mutant MTC previously refractory to non-selective kinase inhibition.
Uptime monitoring gives MEN2 tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to hereditary endocrine tumor programs, multidisciplinary MEN2 clinics, endocrine surgery centers, and oncology RET inhibitor programs that platform operational reliability matches the prophylactic-surgery-timing urgency, pre-surgical pheochromocytoma biochemistry requirements, calcitonin doubling time surveillance intensity, and selective RET inhibitor treatment continuity demands of modern MEN2 care.
Start monitoring your MEN2 care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #MEN2 #multiple #endocrine #neoplasia #RET #protooncogene #medullary #thyroid #carcinoma #MTC #pheochromocytoma #calcitonin #selpercatinib #pralsetinib #vandetanib #cabozantinib #prophylactic #thyroidectomy #ATA #risk #category #MEN2B #mucosal #neuromas #hereditary #cancer #HIPAA #healthtech #digitalhealth #uptime #sre